On 25 November, the Federation of European Academies of Medicine (FEAM), with the support of Novartis, is hosting a joint activity discussing and examining drug development within the European Union and beyond. Prior to the arrival of any medicine on the market, each product goes through a lengthy research and development process which is tested for safety and efficacy. Stakeholders at all stages in this process have drawn attention to length, complexity, costs, hard to retrieve data for reproduction, a lack of focus on patient needs as well as a disparity between the pace of innovation and regulatory mechanisms.
Within the EU, once the European Medicines Agency (EMA) approves an intervention, distribution and accessability decisions are then the remit of the Member State that set country specific criteria. In oncology there is a notable gap between pre-approval development of anti-cancer medicines and their post registration use in clinical practice. With academics and researches on one side and industry and clinicians
on the other, any gap in the transfer of evidence based knowledge can and will affect optimal implementation.
Therefore, the FEAM’s European Biomedical Policy Forum is organising a public event sponsored by Novartis with the purpose of discussing how this multi-stakeholder network could function more efficiently, identifying challenges and lessons learned to date especially in light of the COVID-19 pandemic. The outcome will be a summary report to inform and empower as cooperation between stakeholders and Member States is vital.
The recording of this event is available here.
Please find the PDF version of the agenda, here.
If you have any queries, please contact Elisa Corritore: email@example.com